Latest news

Alvotech’s Proposed Interchangeable Product for High-Concentration Humira® Could Save U.S. Consumers and Taxpayers Billions Annually In May of 2021, Alvotech USA Inc. Sued to End AbbVie’s Wrongful Monopoly on Humira...

Róbert Wessman, Chairman of Alvotech, presented at the Jefferies Global Healthcare Conference, that took place in virtual format on June 1-4, 2021.

The latest outbreak of Covid-19 in India, hit close to home for Alvotech employees as many colleagues have relocated to Iceland from India to join the company. In a gesture...

Federal Court Filing Details AbbVie’s Continued Attempts to Squash Competition Over America’s Highest Grossing Prescription Drug Alvotech’s New Biosimilar Drug Would Provide Immediate Savings to Consumers Alvotech today filed a...

Alvotech and the Icelandic sports club KR have signed a collaboration agreement for the 2021 season. Robert Wessman, Chairman of Alvotech and Pall Kristjansson, Head of KR’s football division, signed...

Alvotech strongly disputes AbbVie’s allegations of wrongdoing relating to AVT02, Alvotech’s proposed biosimilar to HUMIRA® (adalimumab).

Alvotech has successfully completed a second round of its US$ 100 million private placement, for US$ 35 million.

Birna Thórarinsdóttir, Executive Director at UNICEF Iceland, and Robert Wessman, the Chairman and Founder Alvotech, signed a collaboration agreement today, under which the companies, Alvotech and sister company Alvogen​​ will...

Cipla Gulf and Alvotech today announced that they are expanding their partnership for the marketing and distribution of four biosimilar medicines in Australia and New Zealand.

The Equal pay certification follows a rigorous process requiring specific policies, processes and controls to be implemented.

A ground-breaking ceremony for the extension of Alvotech's high-tech centre in Reykjavík took place today. Robert Wessman, Chairman of the Board, Dagur B. Eggertsson, Mayor of Reykjavik and Jon Atli...

Fuji Pharma will exclusively commercialize the medicines in Japan – discussions between the parties continue over additional biosimilar candidates

Alvotech hf. and Alvotech & CCHT Biopharmaceutical Co., Ltd., which is the China joint venture company of Alvotech hf. and Changchun High & New Technology Industries (Group) Inc., have partnered...

Alvotech is developing AVT02 as a proposed biosimilar to HUMIRA® (adalimumab) with high concentration (100mg/mL) dosage forms AVT02 is highly similar to its reference product in terms of structure and...

Alvotech and Cipla Medpro, a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited, have entered into an exclusive partnership to bring key biosimilars to patients in emerging markets...

Alvotech announced today that its parent company, Alvotech Holdings SA, has successfully completed a $65 million private placement round.

Alvotech and DKSH, a leading healthcare provider across 36 emerging countries in South-East Asia, today announced an expansion of their strategic partnership to commercialize six new biosimilar product candidates for...

Alvotech and Teva bring together highly complementary capabilities to secure a leading position in the U.S. biosimilar market The collaboration is one of the broadest partnerships within the U.S....

Alvotech today announced the appointment of Tanya Zharov as deputy chief executive officer in Iceland. Tanya's principal responsibilities will be oversight of Icelandic operations and administration, including the Reykjavik site...

Alvotech is developing AVT02 as a proposed biosimilar to HUMIRA® (adalimumab) with high concentration (100mg/mL) dosage forms The Phase 1 PK similarity study for AVT02 (AVT02-GL-101) has met its primary...

We are excited to announce the launch of our new brand identity for our B2B business, Adalvo. Why ‘Adalvo’? Our B2B business has seen tremendous growth in recent...